Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France. “

Several other equities research analysts also recently issued reports on the company. BidaskClub raised Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a strong sell rating to a sell rating in a research report on Saturday, December 9th. Roth Capital set a $14.00 price target on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the company a buy rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $21.50.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) traded up $0.19 during trading on Tuesday, reaching $9.29. 403,184 shares of the company’s stock traded hands, compared to its average volume of 198,371. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47. The firm has a market capitalization of $364.77, a P/E ratio of 4.81 and a beta of 1.34. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 52-week low of $7.52 and a 52-week high of $12.30.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last posted its earnings results on Wednesday, November 8th. The company reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.13. The firm had revenue of $39.68 million for the quarter, compared to the consensus estimate of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.08) earnings per share. equities research analysts forecast that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.32 EPS for the current year.

In related news, Director Craig R. Stapleton sold 254,265 shares of the stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.35, for a total value of $2,377,377.75. Following the completion of the sale, the director now owns 253,413 shares in the company, valued at $2,369,411.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Craig R. Stapleton bought 140,000 shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average price of $8.67 per share, with a total value of $1,213,800.00. The disclosure for this purchase can be found here. Company insiders own 5.07% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVDL. Sei Investments Co. lifted its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after buying an additional 2,900 shares during the period. State of Tennessee Treasury Department bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter valued at about $194,000. JPMorgan Chase & Co. bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter valued at about $733,000. PNC Financial Services Group Inc. lifted its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% in the second quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after buying an additional 10,532 shares during the period. Finally, GSA Capital Partners LLP lifted its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 9.9% in the second quarter. GSA Capital Partners LLP now owns 200,213 shares of the company’s stock valued at $2,208,000 after buying an additional 18,056 shares during the period. Institutional investors and hedge funds own 67.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Downgraded by Zacks Investment Research to Sell” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2018/01/10/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-downgraded-by-zacks-investment-research-to-sell.html.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit